Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HIV-2 evades restriction by ZAP through adaptations in the U3 LTR region despite increased CpG levels.

Nucleic acids research·2025

Same author

Evaluation of the effect of RNA secondary structure on Cas13d-mediated target RNA cleavage.

Molecular therapy. Nucleic acids·2024

Same author

Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.

Journal of virology·2024

Same author

CRISPR-Cas attack of HIV-1 proviral DNA can cause unintended deletion of surrounding cellular DNA.

Journal of virology·2023

Same author

HIV-1 3'-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles.

Journal of virology·2023

Same author

HIV co-opts a cellular antiviral mechanism, activation of stress kinase PKR by its RNA, to enable splicing of rev/tat mRNA.

Cell & bioscience·2023

Same journal

HIV ribonuclease H: continuing the search for small molecule antagonists.

HIV therapy·2024

Same journal

Type I interferon in HIV treatment: from antiviral drug to therapeutic target.

HIV therapy·2020

Same journal

Implementation of cervical cancer prevention services for HIV-infected women in Zambia: measuring program effectiveness.

HIV therapy·2014

Same journal

Switching antiretroviral therapy to minimize metabolic complications.

HIV therapy·2011

Same journal

Regulatory T cells in HIV immunotherapy.

HIV therapy·2011

Same journal

Recent developments in HIV-related kidney disease.

HIV therapy·2011

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

Possible applications for replicating HIV 1 vectors.

Atze T Das¹, Rienk E Jeeninga, Ben Berkhout

¹Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection & Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands.

|June 29, 2010

Summary

This summary is machine-generated.

Researchers explored conditionally replicating HIV-1 vector systems for novel applications. These systems show promise for live attenuated vaccines, cancer virotherapy, and gene therapy, despite safety considerations.

More Related Videos

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Related Experiment Videos

Last Updated: Jun 11, 2026

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles

Published on: April 8, 2012

Area of Science:

Virology
Gene Therapy
Oncology

Background:

Human Immunodeficiency Virus type 1 (HIV-1) research has advanced understanding of its replication.
Lentiviral vector systems, derived from HIV-1, offer advantages over traditional retroviral vectors.
Current lentiviral vectors are replication-incompetent for safety, minimizing risks of replication-competent virus generation.

Purpose of the Study:

To review activities and potential applications of replication-competent HIV-1 based vector systems.
To explore the use of these vectors in vaccine development, cancer virotherapy, and gene therapy.

Main Methods:

Generation of a conditionally replicating HIV-1 variant for live attenuated virus vaccine development.
Construction of mini HIV variants for cancer-selective virotherapy against leukemia.
Development of a conditionally live anti-HIV gene therapy vector.

Main Results:

Promising results observed in cell culture systems for all explored applications.
Demonstrated potential for a safe live attenuated virus vaccine.
Showcased cancer-selective targeting for leukemia virotherapy.
Indicated feasibility of a conditionally live anti-HIV gene therapy vector.

Conclusions:

Replication-competent HIV-1 based vector systems, despite safety concerns, show significant promise.
Further testing in animal models is warranted to validate these findings.
These novel vector systems could lead to advancements in vaccines, cancer treatment, and gene therapy.